Levi Hoste (Belgium)

Ghent University Hospital Pediatrics

Author Of 1 Presentation

SAFETY OF COVID-19 VACCINATION IN CHILDREN WITH A HISTORY OF MIS-C: AN INTERNATIONAL SURVEY

Date
Fri, 13.05.2022
Session Time
10:00 - 11:30
Session Type
Oral Presentations Session
Room
BANQUETING HALL
Lecture Time
10:02 - 10:12

Abstract

Backgrounds:

Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe SARS-CoV-2 related disease occurring in children and adolescents. Its pathophysiology is incompletely unraveled, although superantigen-driven hyperinflammation is presumed. Currently approved pediatric vaccines against coronavirus disease 2019 (COVID-19) are mRNA-based and encode the SARS-CoV-2 spike protein. Theoretically, in children with previous MIS-C, re-exposure to the same viral protein could trigger hyperinflammation. However, to date, no specific safety data for COVID-19 vaccination are available for children with a history of MIS-C.

Methods

We conducted an international electronic questionnaire, running from 1 Nov 2021 to 15 Dec 2021.

Results:

We collected data from 83 healthcare professionals involved with MIS-C, originating from 32 countries. Respondents provided information for 5673 MIS-C patients, of which 1750 (30.8%) were eligible for vaccination. Vaccination was documented in 273 (15.6%) children. For 420 additional cases, no contra-indication was in place and, therefore, respondents presumed vaccination without formal registration and vigilance of the procedure.

MIS-C was declared as a contra-indication for COVID-19 vaccination in multiple regions (Belgium/France/Italy/India/Mexico/Pakistan/Turkey/USA), accounting for 1144 patients (20.2% of the cohort). Reasons for contra-indication included national/regional guidelines (9/14 regions) and safety concerns (9/14).

In those vaccinated, mild/moderate adverse events (AE) were reported similarly to those published in healthy controls. Besides one patient experiencing Bell’s palsy, no severe/serious AE were described. In particular, no relapse MIS-C or other similar inflammatory conditions were reported.

Conclusions/Learning Points:

MIS-C is not regarded as a universal contra-indication for COVID-19 vaccination in most countries. In those vaccinated, no particular AE and no relapse MIS-C was reported. At the time of the survey, less than one-third of MIS-C patients were eligible for vaccination and at most 40 percent of those eligible were vaccinated. Further follow-up is warranted.

Hide

Presenter of 1 Presentation

SAFETY OF COVID-19 VACCINATION IN CHILDREN WITH A HISTORY OF MIS-C: AN INTERNATIONAL SURVEY

Date
Fri, 13.05.2022
Session Time
10:00 - 11:30
Session Type
Oral Presentations Session
Room
BANQUETING HALL
Lecture Time
10:02 - 10:12

Abstract

Backgrounds:

Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe SARS-CoV-2 related disease occurring in children and adolescents. Its pathophysiology is incompletely unraveled, although superantigen-driven hyperinflammation is presumed. Currently approved pediatric vaccines against coronavirus disease 2019 (COVID-19) are mRNA-based and encode the SARS-CoV-2 spike protein. Theoretically, in children with previous MIS-C, re-exposure to the same viral protein could trigger hyperinflammation. However, to date, no specific safety data for COVID-19 vaccination are available for children with a history of MIS-C.

Methods

We conducted an international electronic questionnaire, running from 1 Nov 2021 to 15 Dec 2021.

Results:

We collected data from 83 healthcare professionals involved with MIS-C, originating from 32 countries. Respondents provided information for 5673 MIS-C patients, of which 1750 (30.8%) were eligible for vaccination. Vaccination was documented in 273 (15.6%) children. For 420 additional cases, no contra-indication was in place and, therefore, respondents presumed vaccination without formal registration and vigilance of the procedure.

MIS-C was declared as a contra-indication for COVID-19 vaccination in multiple regions (Belgium/France/Italy/India/Mexico/Pakistan/Turkey/USA), accounting for 1144 patients (20.2% of the cohort). Reasons for contra-indication included national/regional guidelines (9/14 regions) and safety concerns (9/14).

In those vaccinated, mild/moderate adverse events (AE) were reported similarly to those published in healthy controls. Besides one patient experiencing Bell’s palsy, no severe/serious AE were described. In particular, no relapse MIS-C or other similar inflammatory conditions were reported.

Conclusions/Learning Points:

MIS-C is not regarded as a universal contra-indication for COVID-19 vaccination in most countries. In those vaccinated, no particular AE and no relapse MIS-C was reported. At the time of the survey, less than one-third of MIS-C patients were eligible for vaccination and at most 40 percent of those eligible were vaccinated. Further follow-up is warranted.

Hide